DDU-IIT is a specialist group within the Drug Development Unit (DDU). The DDU-IIT is integrated within a range of closely linked group working in partnership between the ICR and the Royal Marsden NHS Foundation Trust (RMH). We are also embedded within the cancer Research UK Convergence Science Centre, local drug discovery programmes, the ICR-CTSU and the RMH/ICR Biomedical Research Centre.

We work in close partnership with the ICR Clinical Trials and Statistics Unit (ICR-CTSU), especially with the early phase and adaptive trial group led by Professor Christina Yap. Additionally, we collaborate with our ICR laboratories, including the Clinical Pharmacodynamics Biomarker Group, the Drug Metabolism and Pharmacokinetics Group and the Cancer Biomarkers Group.
The DDU-IIT group brings together the clinical translational scientists and biostatisticians to apply adaptive trial designs to biomarker-led early phase trials for the benefit of cancer patients.

In collaborating with commercial and academic partners our aim is to take forward promising novel therapies, including therapies discovered at the ICR and therapy combinations which would not progress through clinical trials without DDU-IIT sponsorship.

To conduct these trials we work with cancer centres around the UK that are part of the Experimental Cancer Medicine Centres (ECMC) network. We have also established collaborations with institutes outside of the UK such as the Oncology Institute of Southern Switzerland.